PortfoliosLab logoPortfoliosLab logo
TBLA vs. MRNA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

TBLA vs. MRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Taboola.com Ltd. (TBLA) and Moderna, Inc. (MRNA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, TBLA achieves a 1.30% return, which is significantly lower than MRNA's 106.85% return.


TBLA

1D
5.18%
1M
-5.08%
YTD
1.30%
6M
12.26%
1Y
28.65%
3Y*
13.55%
5Y*
10Y*

MRNA

1D
2.79%
1M
30.12%
YTD
106.85%
6M
88.91%
1Y
137.63%
3Y*
-19.86%
5Y*
-22.64%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

TBLA vs. MRNA - Yearly Performance Comparison


2026 (YTD)20252024202320222021
TBLA
Taboola.com Ltd.
1.30%26.30%-15.70%40.58%-60.41%-29.53%
MRNA
Moderna, Inc.
106.85%-29.08%-58.19%-44.63%-29.28%8.33%

Correlation

The correlation between TBLA and MRNA is 0.17, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.17

Correlation (3Y)
Calculated over the trailing 3-year period

0.21

Correlation (All Time)
Calculated using the full available price history since Jun 30, 2021

0.24

Fundamentals

Market Cap

TBLA:

$1.35B

MRNA:

$24.10B

EPS

TBLA:

$0.36

MRNA:

-$8.16

PS Ratio

TBLA:

0.87

MRNA:

10.73

PB Ratio

TBLA:

1.41

MRNA:

3.25

Total Revenue (TTM)

TBLA:

$1.65B

MRNA:

$2.23B

Gross Profit (TTM)

TBLA:

$579.78M

MRNA:

-$309.00M

EBITDA (TTM)

TBLA:

$210.19M

MRNA:

-$3.02B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

TBLA vs. MRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TBLA
TBLA Risk / Return Rank: 6262
Overall Rank
TBLA Sharpe Ratio Rank: 6363
Sharpe Ratio Rank
TBLA Sortino Ratio Rank: 6565
Sortino Ratio Rank
TBLA Omega Ratio Rank: 6262
Omega Ratio Rank
TBLA Calmar Ratio Rank: 6060
Calmar Ratio Rank
TBLA Martin Ratio Rank: 6060
Martin Ratio Rank

MRNA
MRNA Risk / Return Rank: 8686
Overall Rank
MRNA Sharpe Ratio Rank: 8989
Sharpe Ratio Rank
MRNA Sortino Ratio Rank: 8787
Sortino Ratio Rank
MRNA Omega Ratio Rank: 8484
Omega Ratio Rank
MRNA Calmar Ratio Rank: 8888
Calmar Ratio Rank
MRNA Martin Ratio Rank: 8383
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TBLA vs. MRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Taboola.com Ltd. (TBLA) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


TBLAMRNADifference
Sharpe ratioReturn per unit of total volatility

-1.46

Sortino ratioReturn per unit of downside risk

-1.39

Omega ratioGain probability vs. loss probability

1.17

1.33

-0.16

Calmar ratioReturn relative to maximum drawdown

0.80

3.90

-3.10

Martin ratioReturn relative to average drawdown

1.82

7.65

-5.83

TBLA vs. MRNA - Sharpe Ratio Comparison

The current TBLA Sharpe Ratio is 0.63, which is lower than the MRNA Sharpe Ratio of 2.08. The chart below compares the historical Sharpe Ratios of TBLA and MRNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

TBLA vs. MRNA - Drawdown Comparison

The maximum TBLA drawdown since its inception was -85.51%, smaller than the maximum MRNA drawdown of -95.38%. Use the drawdown chart below to compare losses from any high point for TBLA and MRNA.


Loading charts...

Drawdown Indicators


TBLAMRNADifference

Max Drawdown

Largest peak-to-trough decline

-85.51%

-95.38%

+9.87%

Max Drawdown (1Y)

Largest decline over 1 year

-36.01%

-35.51%

-0.50%

Max Drawdown (3Y)

Largest decline over 3 years

-47.84%

-86.58%

+38.74%

Max Drawdown (5Y)

Largest decline over 5 years

-95.38%

Current Drawdown

Current decline from peak

-57.70%

-87.41%

+29.71%

Average Drawdown

Average peak-to-trough decline

-62.39%

-57.16%

-5.23%

Ulcer Index

Depth and duration of drawdowns from previous peaks

15.78%

18.06%

-2.28%

Volatility

TBLA vs. MRNA - Volatility Comparison

The current volatility for Taboola.com Ltd. (TBLA) is 14.77%, while Moderna, Inc. (MRNA) has a volatility of 21.74%. This indicates that TBLA experiences smaller price fluctuations and is considered to be less risky than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


TBLAMRNADifference

Volatility (1M)

Calculated over the trailing 1-month period

14.77%

21.74%

-6.97%

Volatility (6M)

Calculated over the trailing 6-month period

36.70%

51.09%

-14.39%

Volatility (1Y)

Calculated over the trailing 1-year period

45.89%

66.45%

-20.56%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

59.28%

66.76%

-7.48%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

59.28%

72.27%

-12.99%

Dividends

TBLA vs. MRNA - Dividend Comparison

Neither TBLA nor MRNA has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

TBLA vs. MRNA - Financials Comparison

This section allows you to compare key financial metrics between Taboola.com Ltd. and Moderna, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.001.00B2.00B3.00B4.00B5.00B6.00B7.00B20222023202420252026
164.02M
389.00M
(TBLA) Total Revenue
(MRNA) Total Revenue
Values in USD except per share items

Frequently Asked Questions


TBLA and MRNA have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

MRNA has higher volatility (21.74%) compared to TBLA (14.77%). In terms of maximum drawdown, TBLA dropped -85.51% vs MRNA's -95.38%.

MRNA currently has the higher Sharpe Ratio (2.08 vs 0.63), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for TBLA and MRNA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer